Assessment of serological responses to Hepatitis B and Hib vaccines in infants receiving vitamin A (Ghana)

Not Applicable

Completed

• Conditions: Immunology/vaccines; Infections and Infestations; Vaccination again disease

• Registration Number: ISRCTN28820504
• Lead Sponsor: World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)

Brief Summary

2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17449592

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-09-22
• Study Completion: 2006-12-31
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 1077

Inclusion Criteria

1. Live-born infants
2. Willingness of mothers to participate in the study
3. Must reside in the study area for at least 4 months after the birth
4. Consent to two blood samples before and after their child's vaccination

Exclusion Criteria

Does not comply with above inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> The impact of the different doses of vitamin A on the pentavalent vaccines will be assessed by comparing the two groups in terms of their seroconversion rates for:<br> 1. Hepatitis B<br> 2. Haemophilus influenzae type b<br><br> The choice of four months for reevaluation is because this is the age at which it is presently recommended to determine the seroconversion rates. Accordingly, pre-samples will be taken at 6 weeks prior to DPT-HepB Hib immunisation and post samples will be taken at 1 month after the DPT-HepB Hib immunisation.<br>

Secondary Outcome Measures

Name	Time	Method
o secondary outcome measures